SK285940B6 - E-2-[4-(4-chlór-1,2-difenyl-but-1-enyl)fenoxy]etanol a farmaceutický prípravok obsahujúci túto zlúčeninu a táto zlúčenina na lekárske použitie - Google Patents
E-2-[4-(4-chlór-1,2-difenyl-but-1-enyl)fenoxy]etanol a farmaceutický prípravok obsahujúci túto zlúčeninu a táto zlúčenina na lekárske použitie Download PDFInfo
- Publication number
- SK285940B6 SK285940B6 SK1205-2000A SK12052000A SK285940B6 SK 285940 B6 SK285940 B6 SK 285940B6 SK 12052000 A SK12052000 A SK 12052000A SK 285940 B6 SK285940 B6 SK 285940B6
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- diphenyl
- chloro
- ethanol
- phenoxy
- Prior art date
Links
- LUMKNAVTFCDUIE-WCWDXBQESA-N 2-[4-[(e)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(/CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-WCWDXBQESA-N 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 150000001875 compounds Chemical class 0.000 title description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 47
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 6
- 238000002657 hormone replacement therapy Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 9
- 229960005026 toremifene Drugs 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- -1 4-chloro-1,2-diphenyl-but-1-enyl Chemical group 0.000 description 5
- 230000001833 anti-estrogenic effect Effects 0.000 description 5
- 230000001076 estrogenic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000009806 oophorectomy Methods 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 229960004622 raloxifene Drugs 0.000 description 4
- OYXIKBMCUBZEPS-NVQSTNCTSA-N (e)-3,4-diphenyl-4-[4-(2-phenylmethoxyethoxy)phenyl]but-3-en-1-ol Chemical compound C=1C=CC=CC=1C(/CCO)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 OYXIKBMCUBZEPS-NVQSTNCTSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XARXSXPYKRGUFO-NVQSTNCTSA-N 1-[(e)-4-chloro-1,2-diphenylbut-1-enyl]-4-(2-phenylmethoxyethoxy)benzene Chemical compound C=1C=CC=CC=1C(/CCCl)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 XARXSXPYKRGUFO-NVQSTNCTSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9803521.5A GB9803521D0 (en) | 1998-02-19 | 1998-02-19 | New compounds and pharmaceutical compositions thereof |
| PCT/FI1999/000137 WO1999042427A1 (en) | 1998-02-19 | 1999-02-19 | E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK12052000A3 SK12052000A3 (sk) | 2001-01-18 |
| SK285940B6 true SK285940B6 (sk) | 2007-11-02 |
Family
ID=10827263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1205-2000A SK285940B6 (sk) | 1998-02-19 | 1999-02-19 | E-2-[4-(4-chlór-1,2-difenyl-but-1-enyl)fenoxy]etanol a farmaceutický prípravok obsahujúci túto zlúčeninu a táto zlúčenina na lekárske použitie |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6395785B1 (ru) |
| EP (1) | EP1056701B1 (ru) |
| JP (1) | JP2002503713A (ru) |
| KR (1) | KR100755918B1 (ru) |
| CN (1) | CN1161314C (ru) |
| AR (1) | AR014961A1 (ru) |
| AT (1) | ATE252531T1 (ru) |
| AU (1) | AU755798B2 (ru) |
| BG (1) | BG64471B1 (ru) |
| BR (1) | BR9907688A (ru) |
| CA (1) | CA2321122C (ru) |
| CZ (1) | CZ294315B6 (ru) |
| DE (1) | DE69912247T2 (ru) |
| DK (1) | DK1056701T3 (ru) |
| EA (1) | EA002919B1 (ru) |
| EE (1) | EE04233B1 (ru) |
| ES (1) | ES2211038T3 (ru) |
| GB (1) | GB9803521D0 (ru) |
| GE (1) | GEP20022794B (ru) |
| HR (1) | HRP20000545A2 (ru) |
| HU (1) | HUP0101354A3 (ru) |
| ID (1) | ID26857A (ru) |
| IL (1) | IL137214A (ru) |
| NO (1) | NO325595B1 (ru) |
| NZ (1) | NZ505637A (ru) |
| PL (1) | PL193315B1 (ru) |
| PT (1) | PT1056701E (ru) |
| RS (1) | RS49660B (ru) |
| SK (1) | SK285940B6 (ru) |
| TR (1) | TR200002037T2 (ru) |
| UA (1) | UA57132C2 (ru) |
| WO (1) | WO1999042427A1 (ru) |
| ZA (1) | ZA991232B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| SI1235776T1 (sl) * | 1999-11-16 | 2006-06-30 | Hormos Medical Corp | Trifenilalkenski derivati in njihova uporaba kot selektivni estrogenski receptorski modulatorji |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| CN101448490A (zh) | 2006-05-22 | 2009-06-03 | 霍尔莫斯医疗有限公司 | 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂 |
| EP2121553B1 (en) | 2007-02-14 | 2012-06-27 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
| US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| CN102770402B (zh) | 2010-01-19 | 2016-01-20 | 坎布雷卡尔斯库加公司 | 制造二苯甲酮衍生物的新方法 |
| JP6174156B2 (ja) | 2012-10-19 | 2017-08-02 | フェルミオン オサケ ユキチュア | オスペミフェンの製造方法 |
| US20150321983A1 (en) * | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
| CN104030896A (zh) * | 2013-03-07 | 2014-09-10 | 天津药物研究院 | 一种简易去除欧司哌米芬特异杂质的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
-
1998
- 1998-02-19 GB GBGB9803521.5A patent/GB9803521D0/en not_active Ceased
-
1999
- 1999-02-16 ZA ZA9901232A patent/ZA991232B/xx unknown
- 1999-02-16 AR ARP990100642A patent/AR014961A1/es active IP Right Grant
- 1999-02-19 TR TR2000/02037T patent/TR200002037T2/xx unknown
- 1999-02-19 PT PT99904899T patent/PT1056701E/pt unknown
- 1999-02-19 WO PCT/FI1999/000137 patent/WO1999042427A1/en active IP Right Grant
- 1999-02-19 AT AT99904899T patent/ATE252531T1/de not_active IP Right Cessation
- 1999-02-19 DE DE69912247T patent/DE69912247T2/de not_active Expired - Fee Related
- 1999-02-19 GE GEAP19995553A patent/GEP20022794B/en unknown
- 1999-02-19 US US09/601,612 patent/US6395785B1/en not_active Expired - Fee Related
- 1999-02-19 CA CA002321122A patent/CA2321122C/en not_active Expired - Fee Related
- 1999-02-19 RS YUP-510/00A patent/RS49660B/sr unknown
- 1999-02-19 AU AU25244/99A patent/AU755798B2/en not_active Ceased
- 1999-02-19 KR KR1020007008982A patent/KR100755918B1/ko not_active IP Right Cessation
- 1999-02-19 ES ES99904899T patent/ES2211038T3/es not_active Expired - Lifetime
- 1999-02-19 BR BR9907688-8A patent/BR9907688A/pt not_active Application Discontinuation
- 1999-02-19 SK SK1205-2000A patent/SK285940B6/sk unknown
- 1999-02-19 HU HU0101354A patent/HUP0101354A3/hu unknown
- 1999-02-19 JP JP2000532381A patent/JP2002503713A/ja active Pending
- 1999-02-19 NZ NZ505637A patent/NZ505637A/xx unknown
- 1999-02-19 CN CNB998030139A patent/CN1161314C/zh not_active Expired - Fee Related
- 1999-02-19 IL IL13721499A patent/IL137214A/xx unknown
- 1999-02-19 EA EA200000851A patent/EA002919B1/ru not_active IP Right Cessation
- 1999-02-19 PL PL342445A patent/PL193315B1/pl unknown
- 1999-02-19 ID IDW20001841A patent/ID26857A/id unknown
- 1999-02-19 CZ CZ20002927A patent/CZ294315B6/cs not_active IP Right Cessation
- 1999-02-19 DK DK99904899T patent/DK1056701T3/da active
- 1999-02-19 EE EEP200000473A patent/EE04233B1/xx not_active IP Right Cessation
- 1999-02-19 EP EP99904899A patent/EP1056701B1/en not_active Expired - Lifetime
- 1999-02-19 UA UA2000095331A patent/UA57132C2/ru unknown
-
2000
- 2000-08-07 NO NO20003987A patent/NO325595B1/no unknown
- 2000-08-18 HR HR20000545A patent/HRP20000545A2/xx not_active Application Discontinuation
- 2000-08-28 BG BG104713A patent/BG64471B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW399036B (en) | Naphthyl compounds, intermediates, pharmaceutical, compositions, and preparation process thereof | |
| EP1169336B1 (en) | Ent-steroids as selectively active estrogens | |
| JP4113583B2 (ja) | 血清コレステロール低下薬 | |
| AU8748991A (en) | Triarylethylene carboxylic acids with estrogenic activity | |
| CZ295939B6 (cs) | Polycyklická sloučenina, obsahující kruhový systém | |
| US20040087565A1 (en) | 9-alpha-substituted estratrienes as selectively active estrogens | |
| EP0615448A1 (en) | Sex steroid activity inhibitors | |
| CA1332742C (en) | Cell growth inhibitors and methods of treating cancer and cell proliferative diseases | |
| SK285940B6 (sk) | E-2-[4-(4-chlór-1,2-difenyl-but-1-enyl)fenoxy]etanol a farmaceutický prípravok obsahujúci túto zlúčeninu a táto zlúčenina na lekárske použitie | |
| KR20010074814A (ko) | 항진균제로서 에스트로겐 화합물의 용도 | |
| JPH09100292A (ja) | 酸化防止作用を有するステロイドを含有する、ヒトにおける薬物ホルモン代用のための製薬学的調剤 | |
| EP0850647B1 (fr) | Application de composés stéroides substitués en ll pour la fabrication de médicaments ayant une activité estrogène dissociée | |
| MXPA00008134A (es) | E-2-[4-(4-cloro-1,2-difenil-but-1-enil)fenoxi]etanol y composiciones farmaceuticas del mismo |